Molecular Pharmacology (USA) Ltd. engages in the development of pharmaceutical products. The company is headquartered in Leederville, Western Australia. The company went IPO on 2005-05-20. Ltd. (MPLA) is in the business of developing and commercializing an analgesic and anti-inflammatory molecule known as Tripeptofen. The Company’s over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs (NSAIDs). The licensed products include all products in all dosage forms, formulations, line extensions and package configurations using production method of metallo-polypeptide analgesic and anti-inflammatory activity as an active ingredient marketed by MPLA or its affiliates under the trade name Tripeptofen. The firm and Molecular Pharmacology Pty. Ltd. have no manufacturing facilities.
